Paul Tudor Jones’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-1,115,371
| Closed | -$21M | – | 1497 |
|
|
2019
Q3 | $21M | Buy |
1,115,371
+1,089,040
| +4,136% | +$12.5M | 0.72% | 12 |
|
|
2019
Q2 | $310K | Buy |
+26,331
| New | +$319K | 0.01% | 850 |
|
|
2019
Q1 | – | Sell |
-18,184
| Closed | -$186K | – | 1342 |
|
|
2018
Q4 | $186K | Sell |
18,184
-16,533
| -48% | -$212K | ﹤0.01% | 879 |
|
|
2018
Q3 | $578K | Buy |
34,717
+22,704
| +189% | +$410K | 0.01% | 642 |
|
|
2018
Q2 | $190K | Buy |
+12,013
| New | +$183K | 0.01% | 936 |
|
|
2017
Q4 | – | Sell |
-111,615
| Closed | -$1.37M | – | 1381 |
|
|
2017
Q3 | $1.37M | Buy |
111,615
+63,311
| +131% | +$660K | 0.03% | 296 |
|
|
2017
Q2 | $553K | Buy |
+48,304
| New | +$893K | 0.02% | 536 |
|
|
2015
Q4 | – | Sell |
-18,017
| Closed | -$590K | – | 1925 |
|
|
2015
Q3 | $590K | Buy |
18,017
+5,035
| +39% | +$214K | 0.02% | 679 |
|
|
2015
Q2 | $688K | Buy |
12,982
+4,166
| +47% | +$152K | 0.02% | 604 |
|
|
2015
Q1 | $254K | Buy |
+8,816
| New | +$242K | 0.01% | 1148 |
|
Paul Tudor Jones's ALDR Position: Q4 2019 in Review
Paul Tudor Jones sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,115,371 shares — an estimated $21M sold.
Paul Tudor Jones first reported a position in ALDR in Q1 2015 and held it in 10 quarters. The position peaked at $21M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Paul Tudor Jones reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Paul Tudor Jones sold 1,115,371 Alder Biopharmaceuticals shares in Q4 2019, an estimated $21M.
- Paul Tudor Jones first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 10 quarters.
- Paul Tudor Jones's Alder Biopharmaceuticals position peaked at $21M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Tudor Investment Corp's 13F filing for Q4 2019, filed 14 Feb 2020.